Search clinical trials for: Ruxolitinib Cream 1.5%

Total 6153 results

Sunnybrook Health Sciences Centre
Novartis

Completed

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Canada
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
University of North Carolina, Charlotte
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis (MSSkin)

Multiple Sclerosis

United States
University of Texas Southwestern Medical Center
GlaxoSmithKline

Recruiting

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis | Amyloidosis

United States
BioCis Pharma Ltd

Completed

Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis

Atopic Dermatitis

Finland
Société des Produits Nestlé (SPN)

Completed

Ketone Plasma Kinetics After Oral Intake Of Different MCT (KetoIndex)

Healthy

Switzerland
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

Sedation

China
Mayo Clinic

Completed

Mesenchymal Stem Cell Therapy for Lung Rejection

Bronchiolitis Obliterans | Lung Transplant Reject

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Centre Hospitalier Universitaire de Nice

Recruiting

Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas (PREVENT)

Vitiligo

France
Novartis Pharmaceuticals
Incyte Corporation

Completed

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)

Cytokine Storm (Covid-19)

United States, Colombia, Turkey, Spain, United Kingdom, Germany, Peru, Russian Federation, Brazil, France, Mexico, Argentina
Grupo Cooperativo de Hemopatías Malignas

Completed

Treatment of SARS Caused by COVID-19 With Ruxolitinib

COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2

Mexico
Kartos Therapeutics, Inc.

Unknown

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Polycythemia Vera

United States, Poland, Spain, Germany, Hungary, France
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
Hennepin Healthcare Research Institute
National Institute of Neurological Disorders and Stroke (NINDS); Strategies...

Recruiting

Hyperbaric Oxygen Brain Injury Treatment Trial (HOBIT)

Traumatic Brain Injury

United States, Canada
LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
Topaz Pharmaceuticals Inc

Completed

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects (LICE OUT)

Head Lice

United States
Sarah Keim
Ohio State University; American Diabetes Association; Ohio Department of Health

Completed

Physical Activity Intervention for Gestational Diabetes (GDM)

Gestational Diabetes

United States
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
Marcelo Iastrebner
Novartis

Unknown

Ruxolitinib in the Treatment of Covid-19

COVID-19
Azienda USL Toscana Nord Ovest
Azienda Ospedaliero, Universitaria Pisana; Azienda Ospedaliera Universitaria... and other collaborators

Unknown

Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection (RESPIRE)

Severe Acute Respiratory Syndrome Coronavirus 2
Dana-Farber Cancer Institute

Terminated

Ruxolitinib in Patients With Breast Cancer

Breast Cancer

United States
John Mascarenhas
National Cancer Institute (NCI); Novartis; Incyte Corporation; Myeloproliferative...

Terminated

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Primary Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Canada, United Kingdom
Medical University of Silesia

Completed

Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With TMD

Cannabis | Myofascial Pain | Temporomandibular Disorder | Electromyography

Poland
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

Chronic Hand Eczema

Belgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Chronic Hand Eczema

Canada, France, Germany, Italy, Poland, United Kingdom
One World Cannabis Ltd.

Completed

A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

Safety Study for Future Treatment of Psoriasis

Israel
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia
Medical University of Lodz

Completed

The Efficacy of a Cosmetic Preparation Containing Sheep Colostrum on Mature Skin (COLMATSKIN)

Skin Aging

Poland
AstraZeneca
Fougera Pharmaceuticals Inc.

Withdrawn

A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis
Serentis Ltd.

Completed

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Pruritus, Atopic Dermatitis

United States
Angelos Kassianos
German Oncology Center, Cyprus; RSL Revolutionary Labs Ltd

Not yet recruiting

Prevention of Radiodermatitis in Breast and Head and Neck Cancer Patients in Cyprus (MEDISKIN)

Breast Cancer | Head and Neck Cancer

Cyprus
Sixera Pharma

Recruiting

A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

Netherton Syndrome

France
AstraZeneca
Fougera Pharmaceuticals Inc.

Withdrawn

A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

Dermatitis
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Oncology Institute of Southern Switzerland

Withdrawn

Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Prostate Cancer

Switzerland
University of Colorado, Denver

Completed

Treatment of Tracheostomy Granulomas

Granuloma | Tracheostomy

United States
Kimberly-Clark Corporation

Completed

A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants

Dermatitis

United States
Tinea Pharmaceuticals

Completed

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

Tinea Pedis

United States
LEO Pharma

Completed

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia

United States
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Atopic Dermatitis Eczema

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer

Lung Cancer

United States, Canada
AstraZeneca

Terminated

GALLANT 7 Tesaglitazar Add-on to Sulphonylurea

Type 2 Diabetes

France, Korea, Republic of, South Africa, Spain, United Kingdom, Vietnam, Norway, Israel, Philippines, Australia
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Stiefel, a GSK Company

Completed

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

Dermatitis, Atopic

United States
Beijing Boren Hospital

Recruiting

Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Peking Union Medical College Hospital

Recruiting

The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia

Severe Checkpoint Inhibitor Pneumonitis

China
M.D. Anderson Cancer Center
Incyte Corporation

Terminated

Phase l/II Study of Ruxolitinib for Acute Leukemia

Leukemia

United States
Washington University School of Medicine
Rigel Pharmaceuticals

Terminated

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Myelofibrosis | Thrombocytopenia

United States

Search clinical trials for: Ruxolitinib Cream 1.5%

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations